Cue Health Stock Price, News & Analysis

Cue Health Inc. was a healthcare technology company that developed diagnostic-enabled care products for at-home and point-of-care testing and later filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code to pursue a wind down of its business. The company, associated with the Nasdaq ticker HLTH in its public releases, was founded in 2010 and headquartered in San Diego, California.

Cue's platform was designed to give individuals and healthcare providers access to lab-quality diagnostic tests outside traditional laboratory settings, including at home and in point-of-care environments. The company also described its offering as including on-demand telehealth consultations and treatment options for health and wellness needs. Its customer categories included federal and state public sector agencies, healthcare providers, enterprises, and individual consumers.

The company's diagnostic portfolio included its COVID-19 test, which received De Novo authorization from the U.S. Food and Drug Administration, and its molecular Mpox test, which received Emergency Use Authorization for point-of-care use. Cue reported ownership of more than 100 patents and positioned its technology around molecular diagnostics, connected testing, and diagnostic-enabled care.

In 2024, Cue announced that it had filed for Chapter 7 bankruptcy protection in the District of Delaware after efforts to reduce costs, improve operating efficiency, obtain additional financing, or complete a strategic transaction. The proceeding was intended to wind down the business, gather and sell company assets, and use proceeds to pay creditors in accordance with the Bankruptcy Code.